Day One Biopharmaceuticals, Inc. (DAWN)
Automate Your Wheel Strategy on DAWN
With Tiblio's Option Bot, you can configure your own wheel strategy including DAWN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Shareholder Alert: The Ademi Firm investigates whether Day One Biopharmaceuticals, Inc. is obtaining a Fair Price for its Public Shareholders
Published: March 06, 2026 by: PRNewsWire
Sentiment: Neutral
MILWAUKEE, March 6, 2026 /PRNewswire/ -- Ademi LLP is investigating Day One (NASDAQ: DAWN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Servier. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.
Read More
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN)
Published: March 06, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, March 6, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) related to its sale to Servier Pharmaceuticals LLC.
Read More
DAWN Stock Alert: Halper Sadeh LLC is Investigating Whether Day One Biopharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
Published: March 06, 2026 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) to Servier for $21.50 per share in cash. Halper Sadeh encourages Day One shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Day One and its board of directors viola.
Read More
Day One Biopharmaceuticals: 'Strong Buy,' Several 2026 Milestones In Play Plus OJEMDA Growth
Published: March 05, 2026 by: Seeking Alpha
Sentiment: Positive
Day One Biopharmaceuticals is maintained at a "Strong Buy" rating, driven by robust pipeline progress and multiple upcoming catalysts. The company's OJEMDA achieved FDA approval and delivered 172% year-over-year revenue growth in 2025, with label expansion efforts underway in pivotal phase 3 trial. Two novel ADC programs, Emi-Le and DAY-301, target high-value oncology indications, with key clinical data readouts expected in mid- and late 2026.
Read More
Day One Biopharmaceuticals: Commercial Performance With Catalysts Ahead
Published: February 27, 2026 by: Seeking Alpha
Sentiment: Positive
Day One Biopharmaceuticals, Inc.'s Q4 '25 came with net product revenues of $52.8M, up 36% from the prior quarter. DAWN's 2026 guidance for U.S. net product revenues of $225M-$250M implies 50% growth over 2025 at the midpoint of that guidance. Key catalysts include clinical readouts from Emi-Le and DAY-301 in 2026. A readout from FIREFLY-2 could come in mid-2027.
Read More
Will Day One Biopharmaceuticals, Inc. (DAWN) Report Negative Earnings Next Week? What You Should Know
Published: February 17, 2026 by: Zacks Investment Research
Sentiment: Negative
Day One Biopharmaceuticals (DAWN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026
Published: February 10, 2026 by: GlobeNewsWire
Sentiment: Neutral
BRISBANE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, February 24, 2026 at 4:30 p.m.
Read More
Wall Street Analysts See a 101.08% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High?
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 101.1% in Day One Biopharmaceuticals (DAWN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Best Momentum Stocks to Buy for January 27th
Published: January 27, 2026 by: Zacks Investment Research
Sentiment: Positive
SHOO, DAWN and MCHP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 27th, 2026.
Read More
Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 107.36%: Read This Before Placing a Bet
Published: January 15, 2026 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Day One Biopharmaceuticals (DAWN) points to a 107.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Day One Biopharmaceuticals (DAWN) Surges 26.7%: Is This an Indication of Further Gains?
Published: January 13, 2026 by: Zacks Investment Research
Sentiment: Positive
Day One Biopharmaceuticals (DAWN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Read More
Day One Completes Acquisition of Mersana Therapeutics
Published: January 06, 2026 by: GlobeNewsWire
Sentiment: Neutral
BRISBANE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the successful close of its acquisition of Mersana Therapeutics, Inc., (NASDAQ: MRSN) (“Mersana”) following completion of all conditions of the tender offer to acquire all outstanding shares of Mersana at a price of $25 per share in cash, plus one non-tradable contingent value right (“CVR”) per share to receive certain potential milestone payments of up to an aggregate of $30.25 per CVR in cash.
Read More
Day One Pharmaceuticals: Stock Surges Ahead Of Promising 2026 - I'm Bullish
Published: December 18, 2025 by: Seeking Alpha
Sentiment: Positive
Day One Biopharmaceuticals, Inc. is gaining momentum after Ojemda's strong Q3 launch, with revenues up 15% sequentially and full-year guidance raised to $145–$150m. DAWN's Ojemda is the only therapy specifically approved for PLGG, with a chance to become standard of care and ongoing Phase 3 front-line study. Strategic moves include acquiring Mersana Therapeutics for ADC pipeline expansion and a lucrative partnership with Ipsen for ex-US commercialization.
Read More
Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference
Published: November 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
BRISBANE, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 4:00 p.m. EST.
Read More
Wall Street Analysts Believe Day One Biopharmaceuticals (DAWN) Could Rally 161.36%: Here's is How to Trade
Published: November 17, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Day One Biopharmaceuticals (DAWN) points to a 161.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Wall Street Analysts See a 234.66% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High?
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 234.7% in Day One Biopharmaceuticals (DAWN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025
Published: October 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
BRISBANE, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, November 4, 2025 at 4:30 p.m. ET to report financial results and discuss corporate progress for the third quarter 2025.
Read More
Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 241.59%: Read This Before Placing a Bet
Published: October 14, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Day One Biopharmaceuticals (DAWN) points to a 241.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Day One Biopharmaceuticals (DAWN) Moves 7.0% Higher: Will This Strength Last?
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Day One Biopharmaceuticals (DAWN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Read More
Wall Street Analysts Believe Day One Biopharmaceuticals (DAWN) Could Rally 303.46%: Here's is How to Trade
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 303.5% in Day One Biopharmaceuticals (DAWN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Day One Biopharmaceuticals: Strong Ojemda Potential In Q2 And Solid Rationale For DAY-301
Published: June 04, 2025 by: Seeking Alpha
Sentiment: Neutral
DAWN reported modest Q1'25 sales growth vs Q4'24, and the reaction of the stock has unsurprisingly been muted. Upcoming Q2'25 earnings are pivotal: confirmation of accelerating growth could spark upside, while continued sluggishness risks further stock stagnation or decline. Potential European approval for Ojemda and phase 1 data from a trial of DAY-301 represent other catalysts ahead, but likely won't provide much news this quarter.
Read More
Day One Biopharmaceuticals, Inc. (DAWN) Q1 2025 Earnings Call Transcript
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Joey Perrone - Senior Vice President, Finance & Investor Relations Jeremy Bender - Chief Executive Officer Lauren Merendino - Chief Commercial Officer Charles York - Chief Operating & Financial Officer Elly Barry - Chief Medical Officer Conference Call Participants Tara Bancroft - TD Cowen Alec Stranahan - Bank of America Soumit Roy - Jones Research Andrea Newkirk - Goldman Sachs Andres Maldonado - H.C. Wainwright Operator Ladies and gentlemen, thank you for standby.
Read More
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q1 Loss, Tops Revenue Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Day One Biopharmaceuticals, Inc. (DAWN) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.72 per share a year ago.
Read More
Day One Biopharmaceuticals, Inc. (DAWN) Q4 2024 Earnings Call Transcript
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Neutral
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Joey Perrone - SVP, Finance and IR Jeremy Bender - CEO Lauren Merendino - CCO Charles York - COO and CFO Conference Call Participants Andrea Newkirk - Goldman Sachs Tara Bancroft - TD Cowen Joe Catanzaro - Piper Sandler Alec Stranahan - Bank of America Andres Maldonado - H.C. Wainwright Operator Hello, ladies and gentlemen, and welcome to the Day One Biopharmaceuticals Fourth Quarter and Full Year 2024 Financial and Operating Results Conference Call.
Read More
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Tops Revenue Estimates
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Negative
Day One Biopharmaceuticals, Inc. (DAWN) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.64 per share a year ago.
Read More
New Strong Buy Stocks for February 13th
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
SYF, SSB, VCYT, DAWN and FISI have been added to the Zacks Rank #1 (Strong Buy) List on February 13, 2025.
Read More
About Day One Biopharmaceuticals, Inc. (DAWN)
- IPO Date 2021-05-27
- Website https://dayonebio.com
- Industry Biotechnology
- CEO Jeremy Bender
- Employees 181